Literature DB >> 63942

Blood groups changes in preleukemic states.

C Salmon.   

Abstract

Modifications of blood groups in the course of malignant hemopathies are related to the disease itself and appear to be essentially clonal. They refer not only to the glycolipidic ABH and associated antigens, but also to other blood group systems or other genetic markers. These multiple abnormalities are observed in the preleukemic states as well as in the actual leukaemias. Similar but limited to one genetic unit abnormalities have been noticed among apparently normal subjects, especially in the aged. The various modifications observed are indeed related to the genetic function, and the clonal character is in favor of this assumption. The evidence of abnormalities affecting two genetic systems which are linked ABO and AK is a further argument supporting this hypothesis. Furthermore, the distribution of immunoglobulin marker abnormalities corresponds to that of one of the haplotypes of the Gm genotype. Finally, we were able to demonstrate that the glycosyltransferase itself is abnormal too, in the case of ABH antigen abnormalities. In all the cases investigated to date, when apparently new characters seemed to be observed, they are in fact unconverted substrates, which are to be compared to the carcinoembryonic antigens.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 63942     DOI: 10.1007/978-3-642-66312-3_14

Source DB:  PubMed          Journal:  Nouv Rev Fr Hematol Blood Cells


  3 in total

1.  Blood Group Change in Pediatric Leukemia: A Rare Phenomena.

Authors:  Venkatraman Radhakrishnan; Sourav Mishra; Narmada Bhaskar; Tenali Sagar
Journal:  Indian J Pediatr       Date:  2016-01-25       Impact factor: 1.967

2.  Blood group change in acute myeloid leukemia.

Authors:  Rakul K Nambiar; Geetha Narayanan; N P Prakash; K Vijayalakshmi
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-01

Review 3.  Preleukemia. Cytogenetic clues in some confusing disorders.

Authors:  P C Nowell
Journal:  Am J Pathol       Date:  1977-11       Impact factor: 4.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.